CN112584825A - 包含甲基磺酰甲烷的用于预防或改善肥胖、脂肪肝及糖尿病的组合物 - Google Patents
包含甲基磺酰甲烷的用于预防或改善肥胖、脂肪肝及糖尿病的组合物 Download PDFInfo
- Publication number
- CN112584825A CN112584825A CN201880096705.4A CN201880096705A CN112584825A CN 112584825 A CN112584825 A CN 112584825A CN 201880096705 A CN201880096705 A CN 201880096705A CN 112584825 A CN112584825 A CN 112584825A
- Authority
- CN
- China
- Prior art keywords
- weight percent
- composition
- msm
- diabetes
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940016409 methylsulfonylmethane Drugs 0.000 title claims abstract description 100
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 title claims abstract description 100
- 239000000203 mixture Substances 0.000 title claims abstract description 97
- 208000008589 Obesity Diseases 0.000 title claims abstract description 42
- 235000020824 obesity Nutrition 0.000 title claims abstract description 42
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 34
- 230000003405 preventing effect Effects 0.000 title claims abstract description 28
- 208000004930 Fatty Liver Diseases 0.000 title claims abstract description 23
- 206010019708 Hepatic steatosis Diseases 0.000 title claims abstract description 23
- 208000010706 fatty liver disease Diseases 0.000 title claims abstract description 23
- 231100000240 steatosis hepatitis Toxicity 0.000 title claims abstract description 23
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 38
- 235000013305 food Nutrition 0.000 claims abstract description 21
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 20
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 19
- 235000019152 folic acid Nutrition 0.000 claims abstract description 18
- 239000011724 folic acid Substances 0.000 claims abstract description 18
- 229960000304 folic acid Drugs 0.000 claims abstract description 18
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims abstract description 12
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 10
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract description 10
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 10
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 10
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 10
- 239000011777 magnesium Substances 0.000 claims abstract description 10
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 10
- 235000009566 rice Nutrition 0.000 claims abstract description 10
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 10
- 239000011718 vitamin C Substances 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 241000209094 Oryza Species 0.000 claims 6
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract description 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 16
- 210000001789 adipocyte Anatomy 0.000 abstract description 15
- 230000004069 differentiation Effects 0.000 abstract description 10
- 210000004185 liver Anatomy 0.000 abstract description 8
- 235000012000 cholesterol Nutrition 0.000 abstract description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 6
- 240000007594 Oryza sativa Species 0.000 abstract description 4
- 230000000225 effect on diabetes Effects 0.000 abstract description 2
- 102000013275 Somatomedins Human genes 0.000 abstract 1
- 235000009200 high fat diet Nutrition 0.000 description 40
- 230000000694 effects Effects 0.000 description 30
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 28
- 239000003814 drug Substances 0.000 description 25
- 238000012360 testing method Methods 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- 235000019197 fats Nutrition 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 20
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 18
- 102000014429 Insulin-like growth factor Human genes 0.000 description 17
- 102000004877 Insulin Human genes 0.000 description 14
- 108090001061 Insulin Proteins 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 229940125396 insulin Drugs 0.000 description 14
- 235000021590 normal diet Nutrition 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 206010022489 Insulin Resistance Diseases 0.000 description 12
- 230000037396 body weight Effects 0.000 description 12
- 238000013116 obese mouse model Methods 0.000 description 12
- 230000028327 secretion Effects 0.000 description 12
- 235000001508 sulfur Nutrition 0.000 description 12
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 11
- 238000009825 accumulation Methods 0.000 description 11
- 230000037406 food intake Effects 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 229910052717 sulfur Inorganic materials 0.000 description 11
- 239000011593 sulfur Substances 0.000 description 11
- 229940124597 therapeutic agent Drugs 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 210000000577 adipose tissue Anatomy 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 239000000122 growth hormone Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 102000018997 Growth Hormone Human genes 0.000 description 7
- 108010051696 Growth Hormone Proteins 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- 230000004130 lipolysis Effects 0.000 description 7
- 210000005228 liver tissue Anatomy 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 208000021017 Weight Gain Diseases 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 210000003494 hepatocyte Anatomy 0.000 description 6
- 230000003914 insulin secretion Effects 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 235000019786 weight gain Nutrition 0.000 description 6
- -1 aromatics Substances 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000208340 Araliaceae Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 235000008434 ginseng Nutrition 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 210000000653 nervous system Anatomy 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229960004425 sibutramine Drugs 0.000 description 3
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- 208000013824 Acidemia Diseases 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 235000021068 Western diet Nutrition 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- JLQNHALFVCURHW-UHFFFAOYSA-N cyclooctasulfur Chemical compound S1SSSSSSS1 JLQNHALFVCURHW-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000016097 disease of metabolism Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229960001582 fenfluramine Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 210000000229 preadipocyte Anatomy 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 235000019159 vitamin B9 Nutrition 0.000 description 2
- 239000011727 vitamin B9 Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000015121 Cardiac valve disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 235000005205 Pinus Nutrition 0.000 description 1
- 241000218602 Pinus <genus> Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
- XRQZZRAWRHFHSV-UHFFFAOYSA-N S(=O)(=O)(O)NC(=O)N.S(=O)(=O)=NC(=O)N Chemical compound S(=O)(=O)(O)NC(=O)N.S(=O)(=O)=NC(=O)N XRQZZRAWRHFHSV-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229930003761 Vitamin B9 Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003048 aphrodisiac agent Substances 0.000 description 1
- 230000002509 aphrodisiac effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229910052798 chalcogen Inorganic materials 0.000 description 1
- 150000001787 chalcogens Chemical class 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 229960004597 dexfenfluramine Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940074046 glyceryl laurate Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000027700 hepatic dysfunction Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229940124706 obesity therapeutics Drugs 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002898 organic sulfur compounds Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 201000008312 primary pulmonary hypertension Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 1
- 238000003044 randomized block design Methods 0.000 description 1
- 108010077161 rat insulin-like growth factor-1 Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pediatric Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及包含甲基磺酰甲烷的用于预防或改善肥胖、脂肪肝及糖尿病的组合物,包含75重量百分比至85重量百分比的甲基磺酰甲烷(MSM,Methyl Sulfonyl Methane:Dimethyl Sulfone)、0.5重量百分比至2重量百分比的维生素B6盐酸盐、0.01重量百分比至1重量百分比的叶酸(folic acid)、2重量百分比至8重量百分比的低聚半乳糖、10重量百分比至18重量百分比的大米发酵镁以及0.5重量百分比至3重量百分比的维生素C的本发明的包含MSM的组合物减少脂肪细胞的大小并抑制成熟脂肪细胞的分化,从而不仅可以预防及治疗肥胖,而且还通过降低肝内甘油三酯及总胆固醇的浓度来产生脂肪肝预防效果,并通过降低胰岛素样生长因子的浓度来对糖尿病产生效果。因此,期待有效用作用于预防及改善肥胖、脂肪肝及糖尿病的药学及食品组合物。
Description
技术领域
本发明涉及包含甲基磺酰甲烷的用于预防或改善肥胖、脂肪肝及糖尿病的组合物。
背景技术
随着诸如饮食习惯等的生活环境的变化,内脏脂肪型肥胖增加,伴随脂肪肝、脂质代谢紊乱、糖尿病、胰岛素抵抗、高血压等的代谢综合征(metabolic syndrome)的发病正日益成为社会问题。这些疾病增加了彼此之间的发病风险,并且是与多种生物代谢变化相关的常见疾病,例如衰老、压力和免疫功能下降等。
脂肪肝被认为是以由慢性酒瘾、暴饮暴食引起的肥胖症和糖尿病为主要原因,此外,在服用高毒性药物、怀孕期间误服抗生素、在儿童患有发热性感染疾病时出于解热目的滥用阿斯匹林的情况下,会发生脂肪肝。这种脂肪肝若免疫状态等身体素质良好就容易通过肝细胞的再生来恢复,否则,肝细胞中的脂肪块变大的同时使包括核在内的细胞的重要组成成分推向一侧导致肝细胞的功能下降,由堆积在细胞内的脂肪膨胀的肝细胞压迫肝细胞之间的微血管和淋巴腺,导致肝内的血液和淋巴液的循环发生障碍,肝细胞无法适当地接收氧和营养供给,因此肝功能下降,甚至会发生肝硬化。
高血脂症是在血液中的脂肪成分物质过多,并堆积在血管壁上引起炎症,从而引起心血管疾病的状态,分为高中性脂肪血症和高胆固醇血症,最近,称为血脂异常症(dyslipidemia)的在血液中的中性脂肪、总胆固醇及LDL-胆固醇增加或者HDL-胆固醇减少的状态也包括在高脂血症的一种。此疾病虽然没有特别的症状,但会成为动脉硬化的原因,由此可发生冠状动脉心脏疾病或脑血管疾病、周围血管病等。不仅如此,脂肪堆积过度也会对肝造成影响,因此,还可与脂肪肝的发生密切相关。
肥胖不仅是体重过重,而且还可以指体脂过度堆积的状态。虽然从外表看是正常体重,但体脂高就可称为肥胖。一般而言,判定肥胖的方法利用身体质量指数(BMI),当身体质量指数为23~24.9时,判定为体重过重,当身体质量指数为25~29.9时,判定为轻度肥胖,当身体质量指数为30~34.9时,判定为中度肥胖,当身体质量指数为35以上时,判定为高度肥胖。肥胖是由多种原因复合引起的,而不是单一原因引起的,例如,包括西式饮食在内的不良饮食习惯、活动量减少、情绪因素、遗传因素等,由此引起的肥胖最终提升高脂血症、糖尿病、高血压等慢性疾病的发病危险。
肥胖是指体内脂肪堆积过多的状态,相当于男性的体脂率为25%,女性的体脂率为30%以上,或者身体质量指数(BMI,Body mass index)为30kg/m2以上。导致肥胖的环境因素为由生活习惯的变化引起的热量摄入过多和缺乏运动。另一方面,与肥胖有关的糖尿病分为胰岛素依赖型糖尿病(1型糖尿病)、非胰岛素依赖型糖尿病(2型糖尿病)及营养不良相关性糖尿病(MRDM),据报道,占韩国糖尿病患者的90%以上的2型糖尿病为以高血糖为特征的代谢疾病,由遗传、代谢、环境因素导致的胰岛β细胞的胰岛素分泌降低或者末梢组织中的胰岛素抵抗增加导致。糖尿病在其发病机理中与肥胖有非常密切的关系,因此,若体脂因为肥胖而增加,则出现胰岛素敏感性降低的症状,并且,在患有2型糖尿病的患者中,肥胖与胰岛素抵抗密切相关,因此,肥胖越严重,胰岛素抵抗也越严重。
现有的用于治疗肥胖的治疗剂可大致分为通过作用于中枢神经系统来影响食欲的药物和通过作用于胃肠道来抑制吸收的药物。作为作用于中枢神经系统的药物,根据各个机制来抑制血清素(5HT)神经系统的芬氟拉明、右芬氟拉明等药物;通过去甲肾上腺素神经系统的麻黄碱及咖啡因等药物;以及最近的通过同时作用于血清素及去甲肾上腺素神经系统来抑制肥胖的西布曲明(Sibutramine)药物在市售中。此外,通过作用于胃肠道来抑制肥胖的代表性的药物为通过抑制在胰脏中生成的脂肪酶来降低脂肪的吸收的最近被批准用作肥胖治疗剂的奥利司他等。但是,以往使用的肥胖治疗剂中的芬氟拉明等由于产生如原发性肺动脉高压或心脏瓣膜病变等副作用,因此被禁止使用,西布曲明具有增加血压的副作用,奥利司他具有消化道障碍等副作用。并且,其他化学合成药物也发生血压降低或乳酸血症等问题,因此,存在无法在患有心脏衰竭及肾脏疾病等患者中使用的问题。
即,需要现有的治疗剂所具有的副作用少且预防或治疗肥胖及与此密切相关的糖尿病的方法,近来,正在积极进行从天然材料中寻找解决方案的研究。即,需要在利用天然材料的同时通过抑制体重增加、减少脂肪堆积、减少脂肪细胞大小、改善脂肪肝、改善血液中脂质、降低血糖及减少胰岛素抵抗的效果来产生抗肥胖及抗糖尿功能的治疗方法,本发明考虑这些问题而提出。
糖尿病(diabetes)为血液中存在的葡萄糖通过尿液被排放的疾病,是指表现出由胰岛素的分泌缺陷或胰岛素作用的缺陷引起的慢性高血糖症的特征的多重病因的代谢障碍。糖尿病可大致分为1型糖尿病(胰岛素依赖型)及2型糖尿病(非胰岛素依赖型),2型糖尿病的病因为两种,即,胰岛素分泌障碍和胰岛素抵抗(insulin resistance)的复合障碍。
糖尿病的95%以上为2型糖尿病,由于包括由经济的快速发展导致的西式饮食生活的生活环境变化、各种压力增加及人口老龄化等,这种疾病正在急剧增加。
被称为代表性的成人代谢疾病的糖尿病蔓延到消化性糖尿病,人们对其影响感到非常担忧。在全世界人口中,约5%的人口患有糖尿病,韩国的糖尿病发病率达5%~10%,截至2014年,主要死因的死亡率为每10万人中20.7人,在韩国慢性疾病死亡率中,死亡顺序依次为癌症、心脏疾病、脑血管疾病、缺血性心脏病和糖尿病,由此导致的人员、经济损失巨大(韩国统计厅,2015)。
胰岛素分泌障碍是指适当量的胰岛素在胰岛β细胞中不随着血糖浓度分泌的现象。这是因为分泌胰岛素的β细胞的数量减少或β细胞的功能分配障碍产生的现象。
胰岛素抵抗是指所分泌的胰岛素虽然随着血流到达目标器官,但在其靶细胞中的胰岛素作用及敏感性降低的现象。通常,被认为是胰岛素与细胞膜胰岛素受体结合后所产生的细胞内信号的强度是通过某种原因变弱的信号传递障碍。胰岛素分泌障碍和胰岛素抵抗复合作用,使糖尿病更加恶化。即,若存在胰岛素抵抗,则为了克服抵抗而需要分泌更多的胰岛素,相反,由胰岛素的分泌不足而引起的高血糖自身会使胰岛素抵抗再次恶化。
当前,作为非胰岛素依赖型糖尿病的治疗方法有饮食疗法、运动疗法、药物疗法等。药物疗法中,在临床上适用增加胰岛素分泌功能的磺醯尿素(sulfonlurea)类药物、提高胰岛素作用力的过氧化物酶体增殖物激活受体γ(PPAR-γ,peroxisome proliferatoractivated receptor gamma)抑制剂类药物、通过干扰碳水化合物的消化吸收来防止饭后血糖上升的α-葡萄糖苷酶抑制剂类药物(例如,阿卡波糖(acarbose))、促进细胞吸收葡萄糖的双胍(biguanide)类药物(例如,二甲双胍(metformin))、作用时间多样化的胰岛素等。
但是,这些治疗剂存在药效弱或者引起肝功能在障碍、低血糖、乳酸血症等很多副作用的问题。因此,需要开发降低这种副作用并在长期服用时也具有优秀的稳定性的糖尿病治疗剂。根据这种需求,正在积极进行从天然物中探索糖尿病治疗药物的研究,在1990年,世界卫生组织(WHO)也积极推荐了利用对糖尿病具有效果且副作用少的天然物(GroverJ.K.et al.,J.Ethnopharmacol.,73,pp 461-470,2000)。
但是,虽然严格的血糖调节可预防或延迟糖尿病性并发症的发生,对2型糖尿病的治疗有效的药材在预防严格的血糖调节或糖尿病的并发症时存在很多缺点,因此需要开发新的治疗剂。
另一方面,通常,硫(sulfur)为属于元素周期表的第6B族的氧族元素(元素符号:S,原子序数:16,原子量:32.06,熔点:112.8℃(α硫),沸点:444.7℃,比重:2.07(α硫)),其在地球上作为自然硫以游离状态生成,而且还以化合物的状态广泛存在。硫是人体中第四大最丰富的矿物质,仅次于钙、磷和钾,可在体内的所有细胞中发现,是作为重要氨基酸的胱氨酸(Cystine)、半胱氨酸(Cysteine)、甲硫氨酸(Methionine)的组成成分,对细胞的生命不可缺少,并且,其为作为维生素的硫胺素和生物素的组成成分,而且还存在于唾液和胆汁及作为激素的胰岛素中。
这种硫占人的体重的0.15%,体内矿物质含量的10%为硫。像这样,硫为在生物的呼吸、同化作用等新陈代谢活动中不可缺少的最重要的物质之一。从远古时代开始知道,硫具有保护人的阳气的效果。合法的硫为最好的壮阳剂,用作治疗阳气不足、各种溃疡和炎症及包括寒症在内的小儿妇科疾病的药。许浚的《东医宝鉴》中记载了“硫虽然热量高且毒性强,但可通过驱赶体内寒气来治疗阳气不足,而且治疗心腹(胸和腹)的积聚(在中医中,由于长期食而在腹内结块的疾病)和邪气(在中医中,致病的风寒暑湿之类的恶气)。并且,硫被单独释放”。
甲基磺酰甲烷(MSM,Methyl Sulfonyl Methane:Dimethyl Sulfone)为无毒、无味的可食用的硫,在海洋、大气、植物组织、动物组织、人体内等任何地方存在的甲基磺酰甲烷从美国加利福尼亚海松提取,其为在松木素中生成的天然物,将其用作生物成分天然有机硫化合物进行动物毒性实验的结果,相对于1kg的体重,MSM的半数致死量为20g以上,具有与水的半数致死量相同的值,因此,MSM具有接近于水的安全性,即使长期服用也安全。这种MSM的功效为具有减少膝骨关节炎的疼痛、改善皮肤发红、瘙痒的效果。并且,文献[The MSMMiracle.The Official website of the MSM Medical Information Foundation.2005-2006]记载了MSM有效治疗由自身免疫疾病导致的炎症。
维生素B6盐酸盐为水溶性维生素的一种,因此即使摄取过多也不会留存在体内而随着尿液排出,以吡哆醛、吡哆醇、吡哆胺等3种形态存在。其由于干预能量代谢,尤其是蛋白质代谢,所以为对血液、神经系统、免疫系统的重要维生素,叶酸为称为维生素B9或维生素M的维生素的一种。由于对胎儿的神经和血管发育重要,因此,建议孕妇在怀孕之前和怀孕初期服用叶酸,在水果中存在丰富的叶酸。
对此,本发明人在为了开发包含上述的MSM作为有效成分的功能性食品而不断进行研究的过程中,发现包含MSM和维生素B6盐酸盐及叶酸的叶酸减少脂肪细胞的大小并抑制成熟脂肪细胞的分化,从而不仅可以预防及治疗肥胖,而且还可以通过降低肝内甘油三酯及总胆固醇的浓度来产生脂肪肝预防效果,并可以通过降低胰岛素样生长因子的浓度来对糖尿病产生效果,由此完成本发明。
发明内容
技术问题
本发明所要解决的技术问题在于,提供一种用于预防或改善肥胖的药学及食品组合物。
本发明所要解决的再一技术问题在于,提供一种用于预防或改善脂肪肝的药学及食品组合物。
本发明所要解决的另一技术问题在于,提供一种用于预防或改善糖尿病的药学及食品组合物。
解决问题的方案
为了解决上述技术问题,本发明提供一种用于预防或改善肥胖的药学及食品组合物,包含75重量百分比至85重量百分比的甲基磺酰甲烷(MSM,Methyl Sulfonyl Methane:Dimethyl Sulfone)、0.5重量百分比至2重量百分比的维生素B6盐酸盐、0.01重量百分比至1重量百分比的叶酸(folic acid)、2重量百分比至8重量百分比的低聚半乳糖、10重量百分比至18重量百分比的大米发酵镁以及0.5重量百分比至3重量百分比的维生素C。
为了解决上述技术问题,本发明提供一种用于预防或改善脂肪肝的药学及食品组合物,包含75重量百分比至85重量百分比的甲基磺酰甲烷(MSM,Methyl SulfonylMethane:Dimethyl Sulfone)、0.5重量百分比至2重量百分比的维生素B6盐酸盐、0.01重量百分比至1重量百分比的叶酸(folic acid)、2重量百分比至8重量百分比的低聚半乳糖、10重量百分比至18重量百分比的大米发酵镁以及0.5重量百分比至3重量百分比的维生素C。
本发明提供一种用于预防或改善糖尿病的药学及食品组合物,包含75重量百分比至85重量百分比的甲基磺酰甲烷(MSM,Methyl Sulfonyl Methane:Dimethyl Sulfone)、0.5重量百分比至2重量百分比的维生素B6盐酸盐、0.01重量百分比至1重量百分比的叶酸(folic acid)、2重量百分比至8重量百分比的低聚半乳糖、10重量百分比至18重量百分比的大米发酵镁以及0.5重量百分比至3重量百分比的维生素C。
以组合物的总重量为基准,本发明的组合物可包含75重量百分比至85重量百分比的MSM。此时,在MSM的含量小于75重量百分比的情况下,无法得到作为本发明的目标效果的预防肥胖、脂肪肝及糖尿病的效果,在MSM的含量大于85重量百分比的情况下,随着含量的增加,效果不成比例,因此没有效率性,并且存在不能确保制剂稳定性的问题。
上述药学组合物可具有选自由片剂、丸剂、散剂、颗粒剂、胶囊剂、悬浮剂、内用液剂、乳剂、糖浆剂、灭菌水溶液、非水性溶剂、悬浮剂、乳剂、冻干剂及栓剂组成的一种的剂型,可以为用于口服给药或胃肠外给药的多种剂型。当进行制剂化时,使用通常使用的填充剂、增量剂、结合剂、湿润剂、硼解剂、表面活性剂等稀释剂或赋形剂来配制。用于口服给药的固态制剂包括片剂、丸剂、散剂、颗粒剂、胶囊剂等,这种固态制剂通过将一种以上化合物与至少一种如淀粉、碳酸钙、蔗糖(sucrose)或乳糖(lactose)、明胶等赋形剂混合来配制。并且,除了简单的赋形剂之外,还可以使用如硬脂酸镁、滑石等润滑剂。用于口服给药的液态制剂包括悬浮剂、内用液剂、乳剂、糖浆剂等,除了包括作为常用的简单的稀释剂水、液体石蜡之外,还可以包括如湿润剂、甜味剂、芳香剂、保存剂等多种赋形剂。用于胃肠外给药的制剂包括灭菌水溶液、非水性溶剂、悬浮剂、乳剂、冻干制剂、栓剂。作为非水性溶剂、悬浊溶剂,可使用如丙二醇(propylene glycol)、聚乙二醇、橄榄油等植物油、如油酸乙酯等可注射的酯等。作为栓剂的基剂,可使用witepsol、聚乙二醇、吐温(tween)61、可可脂、月桂酸甘油酯、甘油明胶等。
本发明的组合物能够以药学上有效量给药。本发明中,术语“药学上有效量”是指可适用于医学治疗的以合理的利益/风险比治疗疾病的充分的量,有效剂量水平可取决于包括个体种类及重症度、年龄、性别、疾病的种类、药物的活性、对药物的敏感度、给药时间、给药途径及排泄比例、疗程、同时使用的药物的因素及在其他医学领域中公知的因素。本发明的组合物能够作为单独的治疗剂给药或者可与其他治疗剂联用给药,并且可与现有的治疗剂依次或同时给药。而且,可单次或多次给药。重要的是,在考虑所有的上述因素并没有副作用的情况下,给药能够以最小的量获得最大的效果的量,这可由普通技术人员容易决定。本发明的组合物的优选给药量根据患者的状态、体重、疾病的程度、药物形态、给药途径及时间而不同,适当的一日总使用量可在正确的医学判断范围内由主治医师确定,或者通常可将0.001mg/kg至1000mg/kg的量,优选地,0.05mg/kg至200mg/kg的量,更优选地,0.1mg/kg至100mg/kg的量分为一日一次至数次来给药。只要是以分解酒精为目的的个体就不特别限定上述组合物,可适用于任何个体。例如,可适用于如猴、狗、猫、兔、豚鼠、大鼠、小鼠、牛、羊、猪、山羊等非人类动物、人类、鸟类及鱼类等任何个体,给药方式只要是本领域中通常使用的方法就不受限制。例如,可通过口服、直肠或静脉、肌肉、皮下、子宫内膜或脑血管内注射来给药。
作为本发明的一具体实例,本发明提供一种包含MSM作为有效成分的用于预防肥胖、脂肪肝及糖尿病的功能性食品组合物。
当在食品中包含本发明的组合物来使用时,可直接添加上述组合物或者与其他健康食品级健康功能性食品或健康功能食品成分一起使用,可根据常规方法适当使用。可根据使用目的适当决定有效成分的混合量。通常,当制备食品或饮料时,相对于原料,优选地,可添加15重量份以下的本发明的组合物,更优选地,可添加10重量份以下的本发明的组合物。但是,在以健康调节及卫生为目的而长期摄取的情况下,上述量可以为上述范围以下,由于在稳定性方面没有问题,因此,还可使用上述范围以上的量的有效成分。
可包含本发明的组合物的食品的种类不受特别限制,作为具体例,包括肉类、香肠、面包、巧克力、糖果类、点心类、饼干类、披萨、拉面、其他面类、口香糖类、包括冰淇淋类的乳制品、各种汤、饮料、茶、运动饮料、酒精饮料及维生素复合剂等,可包括通常意义上的所有食品,可包括作为使用于动物的饲料利用的食品。并且,在以饮料的形态使用本发明的食品组合物的情况下,像通常的饮料一样,可包含多种甜味剂、香味剂或天然碳水化合物等作为附加成分。上述天然碳水化合物可以为如葡萄糖、果糖等单糖;如麦芽糖、蔗糖等二糖;如糊精、环糊精等多糖;以及如木糖醇、山梨糖醇、赤藓糖醇等糖醇。虽然上述天然碳水化合物的比例不限定于此,但是,相对于每100ml的本发明的组合物,优选地,可以为约0.01g至0.04g,更优选地,可以为0.02g至0.03g。上述甜味剂可以为如索马甜、甜叶菊提取物等天然甜味剂以及如咔啉、阿斯巴甜等合成甜味剂。除了上述之外,本发明的食品组合物还可以包含多种营养剂、维生素、电解质、风味剂、着色剂、果胶酸及其盐、褐藻酸及其盐、有机酸、保护胶体增稠剂、pH调节剂、稳定化剂、防腐剂、甘油、醇类、在碳酸饮料中使用的碳酸化剂等。此外,还可以包含用于制备天然果汁、果汁饮料及蔬菜饮料的果肉。
本发明中,术语“给药”是指以适当的方法向个体导入本发明的药学组合物,给药途径可通过可达到目的组织的口服给药或胃肠外给药等多种途径给药。本发明的治疗方法可包括给药药学有效量的包含上述MSM的药学组合物的步骤。适当的一日总使用量可在正确的医学判断范围内由主治医师确定,通常可将0.001mg/kg至1000mg/kg的量,优选地,0.05mg/kg至200mg/kg的量,更优选地,0.1mg/kg至100mg/kg的量分为一日一次至数次来给药。
但是,考虑本发明的目的,优选地,根据所要达到的反应的种类和程度、包括根据情况是否使用其他制剂在内的具体组合物、患者的年龄、体重、一般健康状态、性别及饮食、给药时间、给药途径及组合物的分泌率、疗程、包括与具体组合物一起使用或者同时使用的药物在内的多种因素以及在医学领域中公知的类似因素,不同程度地适用于对特定患者的具体治疗有效量。
发明的效果
本发明的包含MSM的组合物减少脂肪细胞的大小并抑制成熟脂肪细胞的分化,从而不仅可以预防及治疗肥胖,而且还通过降低肝内甘油三酯及总胆固醇的浓度来产生脂肪肝预防效果,并通过降低胰岛素样生长因子的浓度来对糖尿病产生效果。因此,期待有效用作用于预防及改善肥胖、脂肪肝及糖尿病的药学及食品组合物。
附图说明
本说明书中的附图用于例示本发明的优选实施例,其作用为更好地理解前述的发明的内容和本发明的技术思想,因此,本发明不应解释为仅限定于这些附图中所记载的内容。
图1为通过分为正常饮食组(NCD)、高脂肪饮食组(HFD)、一起摄取高脂肪饮食和包含MSM的组合物(HFD+MSM(0.0088%))的组以及一起摄取高脂肪饮食和包含MSM的组合物(HFD+MSM)(0.017%))的组进行实验的结果来示出包含MSM的组合物对脂肪组织(epididymal cell)的变化产生效果的柱状图。
图2为通过分为本发明的正常饮食组(NCD)、高脂肪饮食组(HFD)、一起摄取高脂肪饮食和包含MSM的组合物(HFD+MSM(0.0088%))的组以及一起摄取高脂肪饮食和包含MSM的组合物(HFD+MSM)(0.017%))的组进行实验的结果来示出包含MSM的组合物对肝组织的变化产生效果的柱状图。
图3为在高脂肪饮食肥胖小鼠模型中摄取包含MSM的组合物后肝组织形态的显微镜照片。
图4为在高脂肪饮食肥胖小鼠模型中摄取包含MSM的组合物后肝组织形态的显微镜照片。
图5为示出在高脂肪饮食肥胖小鼠模型中摄取包含MSM的组合物后3T3-L1细胞的分化抑制效果的显微镜照片。
图6为在肥胖小鼠中测定包含MSM的组合物的肝内甘油三酯的含量变化的柱状图。
图7为在肥胖小鼠中测定包含MSM的组合物的肝内总胆固醇的含量变化的柱状图。
图8为利用加奶咖啡进行的包含MSM的组合物的体外(in vitro)脂肪分解实验结果。
图9为利用参鸡汤进行的包含MSM的组合物的体外(in vitro)脂肪分解实验结果。
图10为示出包含MSM的组合物的IGF-1分泌能力的曲线图。
具体实施方式
以下,为了助于理解本发明,揭示优选实施例等。但是,下述实施例等仅为了更加容易地理解本发明而提供,本发明的内容并不限定于实施例等。
实施例1.包含甲基磺酰甲烷的组合物的制备
制备包含具有如下列表1所示的组分的甲基磺酰甲烷的组合物。
表1
试验例1.高脂肪饮食肥胖小鼠模型中的本发明的组合物的体重增加抑制效果
用固体饲料使作为实验动物的C57BL/6系列8周龄雄性小鼠适应一周后,随机区组设计(randomized block design)将平均体重为25g的小鼠分为3组并饲养8周。
将实验组分为正常饮食组(NCD)、高脂肪饮食组(HFD)、一起摄取高脂肪饮食和在上述实施例1中得到的包含MSM的组合物(HFD+MSM(0.0088%))的组及一起摄取高脂肪饮食和在上述实施例1中得到的包含MSM的组合物包含MSM的组合物(HFD+MSM(0.017%))的组来进行实验。向正常饮食组供给总热量的10%为脂肪的普通饮食,向高脂肪饮食组供给总热量的60%为脂肪的饮食,向一起摄取高脂肪饮食和包含MSM的组合物的组供给添加0.0088%及0.017%的包含MSM的组合物制备的饮食,在饲养期间使动物自由摄取水和饲料。将动物饲养室的温度保持在22.1℃,以12小时的周期调节照明(08:00-20:00),所有动物实验均在获得动物实验伦理委员会(Science and Technology Institutional AnimalCare and Use Committee)的批准下进行,并符合动物实验室伦理原则。
将在实验中获得的各项结果以每实验组的平均标准误差表示,通过t检验(Student's t test)对两组之间的平均差进行统计分析后,在P<0.05水平上验证显著性。
一周一次测量实验动物的食物摄取量及体重。在实验期间以一周为间隔定时测量各实验组的体重增加率,将从供给实验饮食日起至牺牲日为止作为实验期间,实验期间的体重增加量除以实验期间的食物摄取量来计算食物功效比(Food Efficiency Ratio:FER)。
食物摄取量及体重中实验本发明的包含MSM的组合物的效果的每组的结果在表2中示出。
表2
如上述表2所示,相比于正常饮食组,高脂肪饮食组的食物功效比增加约5.4倍,但一起摄取高脂肪饮食和包含MSM的组合物的组的食物功效比减少约1.8倍。另一方面,相比于正常饮食供给组,高脂肪饮食供给组的体重急剧增加,而一起摄取高脂肪饮食和包含MSM的组合物的组的体重增加现象显著减少。经确认,在摄取包含MSM的组合物的情况下,显著地抑制由高脂肪饮食导致的体重增加现象。
试验例2.高脂肪饮食肥胖小鼠模型中的包含MSM的组合物的脂肪堆积抑制效果
以与上述试验例1相同的方式进行实验动物的饲养、饮食及统计处理。为了确认本发明的包含MSM的组合物的脂肪堆积抑制效果,分离实验动物的脂肪、肝组织来测量重量。
图1为通过分为正常饮食组(NCD)、高脂肪饮食组(HFD)、一起摄取高脂肪饮食和包含MSM的组合物(HFD+MSM(0.0088%))的组以及一起摄取高脂肪饮食和包含MSM的组合物(HFD+MSM)(0.017%))的组进行实验的结果来示出包含MSM的组合物对脂肪组织(epididymal cell)的变化产生效果的柱状图。
图2为通过分为本发明的正常饮食组(NCD)、高脂肪饮食组(HFD)、一起摄取高脂肪饮食和包含MSM的组合物(HFD+MSM(0.0088%))的组以及一起摄取高脂肪饮食和包含MSM的组合物(HFD+MSM)(0.017%))的组进行实验的结果来示出包含MSM的组合物对肝组织的变化产生效果的柱状图。
如图1及图2所示,相比于正常饮食组,在高脂肪饮食组中测量出高水平的脂肪组织的重量,一起摄取高脂肪饮食和包含MSM的组合物的组的脂肪组织减少。
试验例2.高脂肪饮食肥胖小鼠模型中的脂肪细胞大小减少及脂肪肝改善效果
以与上述试验例1相同的方式进行实验动物的饲养、饮食及统计处理。为了对实验动物进行形态学观察,将结束实验后取出的各组织去除水分后固定于4%的多聚甲醛溶液中,并将固定完的组织用流水冲洗后,按照依次增加的浓度的顺序,用乙醇脱水,经过渗透过程,包埋在石蜡中,然后,制作4um的组织切片进行苏木精(hematotaxyin)和伊红(eosin)染色后,用光学显微镜观察。
相比于摄取正常饮食的组,摄取高脂肪饮食的组的脂肪细胞大小显著增加,而一起摄取高脂肪饮食和包含MSM的组合物的组的脂肪细胞大小显著减少。经确认,可有效用于由高脂肪饮食引起的肥胖治疗剂预防效果。
图3为在高脂肪饮食肥胖小鼠模型中摄取包含MSM的组合物后肝组织形态的显微镜照片。如图3所示,相比于正常饮食组,摄取高脂肪饮食的组中的脂肪堆积整体性地分布,而一起摄取高脂肪饮食和包含MSM的组合物的组中的脂肪堆积显著减少,这接近于摄取正常饮食的组。因此,分析到包含MSM的组合物有效改善脂肪肝。
图4为在高脂肪饮食肥胖小鼠模型中摄取包含MSM的组合物后肝组织形态的显微镜照片。如图4所示,相比于正常饮食组,摄取高脂肪饮食的组中的脂肪堆积整体性地分布,而一起摄取高脂肪饮食和包含MSM的组合物的组中的脂肪堆积显著减少,这接近于摄取正常饮食的组。
试验例3.高脂肪饮食肥胖小鼠模型中的成熟脂肪细胞分化抑制效果
(1)3T3-L1细胞培养及分化
从美国菌种保藏中心(American Type Culture Collection,ATCC,CL-173,Manassas,VA,USA)接受源自小鼠的3T3-L1细胞来使用。根据实验目的,将1×106细胞/孔(cells/well)的3T3-L1前脂肪细胞分别接种(seeding)于100Φ、24孔板(24-well plate)及96孔板(96-well plate)后,在含有BS(10%)及P/S(1%)的高浓度葡萄糖DMEM(89%)中进行培养,直到达到100%的汇合度(confluence)。两天后,用脂肪细胞分化诱导物质(1μg/mL的胰岛素(insulin)、1μM的DEX、0.5mM的IBMX)和含有FBS(10%)及P/S(10%)的DMEM诱导前脂肪细胞分化为脂肪细胞。当进行脂肪细胞分化(0日)时,对DMEM分别处理25μg/mL、50μg/m及100μg/mL的饲料,对阳性对照组处理5mM的作为抗氧化剂的NAC,然后进行比较。
为了确认3T3-L1细胞分化抑制效果,通过用红色仅染色中性脂肪的油红O(OilRed O)染色法测量3T3-L1脂肪细胞内所生成的中性脂肪的量,其结果如图5所示。
图5为示出在高脂肪饮食肥胖小鼠模型中摄取包含MSM的组合物后3T3-L1细胞的分化抑制效果的显微镜照片。如图4所示,当给药本发明的包含MSM的组合物时,3T3-L1细胞并没有分化。
试验例4.脂肪饮食肥胖小鼠模型中的血液中脂质改善效果
以与上述实验例1相同的方式进行实验动物的饲养、饮食及统计处理。为了确认给药本发明的包含MSM的组合物后血液中脂质改善效果,结束实验后绝食12小时以上后,牺牲所有动物并收集血液。在室温下放置收集到的血液1小时后,利用自动生化分析仪(BS-380,Mindray)对在3000rpm的条件下离心分离30分钟来得到的血清进行肝内甘油三酯及总胆固醇的分析。
图6为在肥胖小鼠中测定包含MSM的组合物的肝内甘油三酯的含量变化的柱状图。
图7为在肥胖小鼠中测定包含MSM的组合物的肝内总胆固醇的含量变化的柱状图。
在这里,向肥胖小鼠给药包含MSM的组合物3周后,通过结果可确认,甘油三酯及总胆固醇含量几乎恢复正常。
试验例5.包含MSM的组合物的体外(in vitro)脂肪分解测定
利用普通加奶咖啡及参鸡汤进行脂肪分解实验。向加奶咖啡中添加本发明的包含MSM的组合物后进行溶解,用肉眼观察脂肪分解。
图8为利用加奶咖啡进行的包含MSM的组合物的体外(in vitro)脂肪分解实验结果。
图9为利用参鸡汤进行的包含MSM的组合物的体外(in vitro)脂肪分解实验结果。
在这里可确认,可用肉眼观察到添加本发明的包含MSM的组合物的加奶咖啡及参鸡汤中的脂肪被分解。
试验例6.包含MSM的组合物的胰岛素样生长因子分泌能力测定
在本试验例中,进行胰岛素样生长因子(IGF-1)对包含MSM的组合物的分泌能力的试验。
使用酶联免疫检测仪(ELIS reader,LAB SYSTEM,USA),ELISA试剂盒(rat IGF-1,catalogue#DSL 10-2900,Diagnostic Systems Laboratories,USA)作为分析仪,使用Prism(ver.2.01,Graphpad Software Inc,USA)作为数据分析及统计系统。
使用SD大鼠(Sprague Dawley rats)作为试验动物。在进行长期给药试验的情况下,试验动物的周龄为3周龄,在进行IGF-1评价试验的情况下,试验动物的周龄为9周龄。试验动物的性别为雄性,给每项试验分配30只(对照组10只、实施例10只、比较例10只)。将试验动物的饲养条件设定成温度为22.3(19~25)℃、湿度为30~70%、光周期(12小时,照明周期:08:00~20:00)。
在进行IGF-1评价试验的情况下,为了调节血液的生长激素的基本量或者为了同时性,将所有动物绝食24小时后使用于试验中。以人和鼠的重量为基准向试验组口服给药一日给药量(以人的体重60kg为基准,一日给药量为1500mg)。向对照组给药与试验组相同的体积的饮用水。在0小时进行尾静脉采血并口服给药后以2小时为间隔采取各0.1ml以内的血液,直到10小时,分离血清来准备待测样品。利用试剂盒产品并通过ELISA方法进行IGF-1测定。
由于大部分的生长激素的分泌通过称为脉冲模式的瞬时释放来进行,因此,很难通过对生理性刺激的反应测量生长激素的分泌量变化。实际上,激素仅在血液中流动几分钟,但足以流入到肝脏后在肝脏中刺激转换为生长激素。为了测量生长激素的分泌量利用IGF-1的分泌,GF-1的作用比生长激素本身更多样化,直接起到大部分的生物学作用。因此,在此试验中测量生长激素的作为二次信号的IGF-1的血液中分泌量,IGF-1在刺激后在血液内保持稳定,实质上呈现出生长激素的效果。
图10为示出包含MSM的组合物的IGF-1分泌能力的曲线图。
在这里可确认,对照组的IGF-1分泌量持续减少,但包含MSM的组合物的IGF-1分泌量显著增加。由此可知,本发明的包含MSM的组合物促进作为胰岛素样生长因子的IGF-1的分泌的效果非常优秀。
Claims (6)
1.一种用于预防或治疗肥胖的药学组合物,其特征在于,包含75重量百分比至85重量百分比的甲基磺酰甲烷、0.5重量百分比至2重量百分比的维生素B6盐酸盐、0.01重量百分比至1重量百分比的叶酸、2重量百分比至8重量百分比的低聚半乳糖、10重量百分比至18重量百分比的大米发酵镁以及0.5重量百分比至3重量百分比的维生素C。
2.一种用于预防或治疗脂肪肝的药学组合物,其特征在于,包含75重量百分比至85重量百分比的甲基磺酰甲烷、0.5重量百分比至2重量百分比的维生素B6盐酸盐、0.01重量百分比至1重量百分比的叶酸、2重量百分比至8重量百分比的低聚半乳糖、10重量百分比至18重量百分比的大米发酵镁以及0.5重量百分比至3重量百分比的维生素C。
3.一种用于预防或治疗糖尿病的药学组合物,其特征在于,包含75重量百分比至85重量百分比的甲基磺酰甲烷、0.5重量百分比至2重量百分比的维生素B6盐酸盐、0.01重量百分比至1重量百分比的叶酸、2重量百分比至8重量百分比的低聚半乳糖、10重量百分比至18重量百分比的大米发酵镁以及0.5重量百分比至3重量百分比的维生素C。
4.一种用于预防或改善肥胖的食品组合物,其特征在于,包含75重量百分比至85重量百分比的甲基磺酰甲烷、0.5重量百分比至2重量百分比的维生素B6盐酸盐、0.01重量百分比至1重量百分比的叶酸、2重量百分比至8重量百分比的低聚半乳糖、10重量百分比至18重量百分比的大米发酵镁以及0.5重量百分比至3重量百分比的维生素C。
5.一种用于预防或改善脂肪肝的食品组合物,其特征在于,包含75重量百分比至85重量百分比的甲基磺酰甲烷、0.5重量百分比至2重量百分比的维生素B6盐酸盐、0.01重量百分比至1重量百分比的叶酸、2重量百分比至8重量百分比的低聚半乳糖、10重量百分比至18重量百分比的大米发酵镁以及0.5重量百分比至3重量百分比的维生素C。
6.一种用于预防或改善糖尿病的食品组合物,其特征在于,包含75重量百分比至85重量百分比的甲基磺酰甲烷、0.5重量百分比至2重量百分比的维生素B6盐酸盐、0.01重量百分比至1重量百分比的叶酸、2重量百分比至8重量百分比的低聚半乳糖、10重量百分比至18重量百分比的大米发酵镁以及0.5重量百分比至3重量百分比的维生素C。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180095802A KR101957502B1 (ko) | 2018-08-17 | 2018-08-17 | 메틸설포닐메탄을 함유하는 비만, 지방간 및 당뇨병 예방 또는 개선용 조성물 |
KR10-2018-0095802 | 2018-08-17 | ||
PCT/KR2018/012675 WO2020036257A1 (ko) | 2018-08-17 | 2018-10-25 | 메틸설포닐메탄을 함유하는 비만, 지방간 및 당뇨병 예방 또는 개선용 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112584825A true CN112584825A (zh) | 2021-03-30 |
Family
ID=65800156
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880096705.4A Pending CN112584825A (zh) | 2018-08-17 | 2018-10-25 | 包含甲基磺酰甲烷的用于预防或改善肥胖、脂肪肝及糖尿病的组合物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20210267912A1 (zh) |
JP (1) | JP2021535121A (zh) |
KR (1) | KR101957502B1 (zh) |
CN (1) | CN112584825A (zh) |
WO (1) | WO2020036257A1 (zh) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4863748A (en) * | 1979-08-30 | 1989-09-05 | Herschler R J | Dietary products and uses comprising methylsulfonylmethane |
CN1425386A (zh) * | 2002-12-25 | 2003-06-25 | 大连鑫碟甲壳素有限公司 | 二甲基砜硫补充剂及其叠加保健品 |
CN1438892A (zh) * | 2000-06-02 | 2003-08-27 | 宝洁公司 | 低碳水化合物组合物、其套盒及其使用方法 |
US20050272714A1 (en) * | 2004-05-06 | 2005-12-08 | Hofmann Robert F | Use of targeted oxidative therapeutic formulation in treatment of diabetes and obesity |
CN101262887A (zh) * | 2005-07-15 | 2008-09-10 | 视可舒研究公司 | 糖尿病的眼科并发症的预防和治疗 |
CN102612371A (zh) * | 2009-10-19 | 2012-07-25 | 莱拉营养食品有限公司 | 含有多聚乙酰的提取物,分馏物和混合物及它们的应用 |
KR20140116606A (ko) * | 2013-03-25 | 2014-10-06 | 이승훈 | 메틸설포닐메탄을 함유하는 혈중 중성지방 저하 및 염증 수치 감소용 기능성 식품 조성물 |
KR20140116988A (ko) * | 2013-03-25 | 2014-10-07 | 이승훈 | 메틸설포닐메탄을 함유하는 류마티스 관절염 및 지질 대사 관련 질환의 예방 및 치료를 위한 약학적 조성물 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2005112667A1 (ja) * | 2004-05-20 | 2008-03-27 | 隆史 大森 | 健康食品 |
CA2634953C (en) * | 2004-12-24 | 2015-09-15 | Dolphst Pty Ltd. | Formulations and treatments for well-being |
KR20070113460A (ko) * | 2006-05-24 | 2007-11-29 | 주식회사 산테 | 체중조절용 건강식품 조성물 |
US9771199B2 (en) * | 2008-07-07 | 2017-09-26 | Mars, Incorporated | Probiotic supplement, process for making, and packaging |
KR101171832B1 (ko) * | 2009-10-30 | 2012-08-14 | 박경식 | 부작용을 제거한 장기간 복용 차 및 그 조성물 |
-
2018
- 2018-08-17 KR KR1020180095802A patent/KR101957502B1/ko active IP Right Grant
- 2018-10-25 WO PCT/KR2018/012675 patent/WO2020036257A1/ko active Application Filing
- 2018-10-25 CN CN201880096705.4A patent/CN112584825A/zh active Pending
- 2018-10-25 JP JP2021510080A patent/JP2021535121A/ja active Pending
- 2018-10-25 US US17/252,676 patent/US20210267912A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4863748A (en) * | 1979-08-30 | 1989-09-05 | Herschler R J | Dietary products and uses comprising methylsulfonylmethane |
CN1438892A (zh) * | 2000-06-02 | 2003-08-27 | 宝洁公司 | 低碳水化合物组合物、其套盒及其使用方法 |
CN1425386A (zh) * | 2002-12-25 | 2003-06-25 | 大连鑫碟甲壳素有限公司 | 二甲基砜硫补充剂及其叠加保健品 |
US20050272714A1 (en) * | 2004-05-06 | 2005-12-08 | Hofmann Robert F | Use of targeted oxidative therapeutic formulation in treatment of diabetes and obesity |
CN101262887A (zh) * | 2005-07-15 | 2008-09-10 | 视可舒研究公司 | 糖尿病的眼科并发症的预防和治疗 |
CN102612371A (zh) * | 2009-10-19 | 2012-07-25 | 莱拉营养食品有限公司 | 含有多聚乙酰的提取物,分馏物和混合物及它们的应用 |
KR20140116606A (ko) * | 2013-03-25 | 2014-10-06 | 이승훈 | 메틸설포닐메탄을 함유하는 혈중 중성지방 저하 및 염증 수치 감소용 기능성 식품 조성물 |
KR20140116988A (ko) * | 2013-03-25 | 2014-10-07 | 이승훈 | 메틸설포닐메탄을 함유하는 류마티스 관절염 및 지질 대사 관련 질환의 예방 및 치료를 위한 약학적 조성물 |
Also Published As
Publication number | Publication date |
---|---|
US20210267912A1 (en) | 2021-09-02 |
KR101957502B1 (ko) | 2019-03-12 |
JP2021535121A (ja) | 2021-12-16 |
WO2020036257A1 (ko) | 2020-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2010267652B2 (en) | Composition and method for reducing food intake | |
JP7011885B2 (ja) | 腸の健康を促す組成物 | |
WO2015072674A1 (ko) | 보리지 추출물을 포함하는 대사질환 개선, 예방 또는 치료용 조성물 | |
KR101213825B1 (ko) | 세린을 유효성분으로 함유하는 지방간 질환의 예방 및 치료용 조성물 | |
US20160074338A1 (en) | Food composition for preventing obesity, pharmaceutical composition for treating obesity, and animal medicine for treating obesity, containing gingernone a | |
KR20160141027A (ko) | 아위버섯 물 추출물을 유효성분으로 함유하는 대사성질환의 예방 및 치료용 약학적 조성물 또는 건강기능성식품 | |
US20030232099A1 (en) | Health-care products and methods for preparing and using the same | |
KR101735061B1 (ko) | 개똥쑥 추출물, 아테미시닌 또는 디히드로아테미시닌을 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물 | |
KR101732483B1 (ko) | 연교 추출물을 유효성분으로 함유하는 말초신경병증 예방, 개선 또는 치료용 조성물 | |
KR102160424B1 (ko) | 유파틸린을 유효성분으로 포함하는 비만 예방, 치료, 또는 개선용 조성물 | |
KR101660834B1 (ko) | 지페노사이드 75의 항당뇨 효과 | |
KR100685472B1 (ko) | 식초 가공 인삼제제를 이용한 제2형 당뇨병과대사증후군의 예방 및 치료용 조성물 | |
CN112584825A (zh) | 包含甲基磺酰甲烷的用于预防或改善肥胖、脂肪肝及糖尿病的组合物 | |
KR101336068B1 (ko) | 한약재의 추출물과 분획물을 포함하는 항당뇨 조성물 | |
KR20180013571A (ko) | 벤토나이트를 유효성분으로 포함하는 항비만 조성물 | |
KR20160094313A (ko) | 모과 추출물 또는 이의 분획물을 유효성분으로 함유하는 항비만용 조성물 | |
KR20100111088A (ko) | 복합 생약 추출물을 유효성분으로 함유하는 당뇨병 또는 이로 인한 합병증의 예방 및 치료용 조성물 | |
KR100535322B1 (ko) | 부추 추출물을 유효성분으로 함유하는 당뇨 질환의 예방및 치료용 약학 조성물 | |
KR20140147482A (ko) | 용담 추출물의 분획물을 유효성분으로 포함하는 당뇨병 전증 또는 당뇨병의 예방 또는 치료용 조성물 | |
CN110404029B (zh) | 一种具有降血糖功效的组合物及其制备方法和应用 | |
KR102189149B1 (ko) | 용담 추출물의 분획물을 유효성분으로 포함하는 당뇨병 전증 또는 당뇨병의 예방 또는 치료용 조성물 | |
KR102318957B1 (ko) | 진세노사이드 mc 또는 mc1을 포함하는 대사성 질환 예방 또는 치료용 조성물 | |
KR100473529B1 (ko) | 순기산 생약 복합제 추출물을 유효성분으로 함유하는당뇨병 예방 및 치료용 조성물 | |
KR100478150B1 (ko) | 생약 복합제 추출물을 유효성분으로 함유하는 당뇨병 예방용 건강보조식품 | |
KR20090021561A (ko) | 호노키올을 유효성분으로 함유하는 지방간 질환의 예방 및치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210330 |
|
WD01 | Invention patent application deemed withdrawn after publication |